Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer

Gynecologic Oncology

Volumn 133, Issue 3, 2014, Pages 599-606

  Konstantinopoulos, Panagiotis A ^a   Wilson, Andrew J ^b   Saskowski, Jeanette ^b   Wass, Erica ^b   Khabele, Dineo ^b,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

Histone deacetylase inhibitors (HDACi); Olaparib (Ola); Ovarian cancer; Phosphorylated gamma histone H2AX (pH2AX); Poly(ADP ribose) polymerase inhibitors (PARPi); Vorinostat (SAHA)

Indexed keywords

DNA; HISTONE H2AX; OLAPARIB; RAD51 PROTEIN; SODIUM CHLORIDE; SULFORHODAMINE B; VORINOSTAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DNA DAMAGE; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IN VITRO STUDY; IN VIVO STUDY; MICROARRAY ANALYSIS; MONOTHERAPY; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; NULL CELL; OVARIAN CANCER CELL LINE; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECOMBINATION REPAIR; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; WESTERN BLOTTING; WILD TYPE;

HISTONE DEACETYLASE INHIBITORS (HDACI); OLAPARIB (OLA); OVARIAN CANCER; PHOSPHORYLATED GAMMA HISTONE H2AX (PH2AX); POLY(ADP-RIBOSE) POLYMERASE INHIBITORS (PARPI); VORINOSTAT (SAHA);

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DNA DAMAGE; DNA, NEOPLASM; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; MICE; MICE, NUDE; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PHTHALAZINES; PIPERAZINES; RECOMBINATIONAL DNA REPAIR; TISSUE ARRAY ANALYSIS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84901684118     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2014.03.007     Document Type: Article

References (39)

1. Integrated genomic analyses of ovarian carcinoma Nature 474 2011 609 615
2. K. Alsop, S. Fereday, C. Meldrum, A. Defazio, C. Emmanuel, and J. George et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group J Clin Oncol 30 2012 2654 2663
3. M.W. Audeh, J. Carmichael, R.T. Penson, M. Friedlander, B. Powell, and K.M. Bell-McGuinn et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial Lancet 376 2010 245 251
4. P.C. Fong, D.S. Boss, T.A. Yap, A. Tutt, P. Wu, and M. Mergui-Roelvink et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers N Engl J Med 361 2009 123 134
5. P.C. Fong, T.A. Yap, D.S. Boss, C.P. Carden, M. Mergui-Roelvink, and C. Gourley et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval J Clin Oncol 28 2010 2512 2519
6. K.A. Gelmon, M. Tischkowitz, H. Mackay, K. Swenerton, A. Robidoux, and K. Tonkin et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study Lancet Oncol 12 2011 852 861
7. J. Ledermann, P. Harter, C. Gourley, M. Friedlander, I. Vergote, and G. Rustin et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer N Engl J Med 366 2012 1382 1392
8. H.E. Bryant, N. Schultz, H.D. Thomas, K.M. Parker, D. Flower, and E. Lopez et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase Nature 434 2005 913 917
9. H. Farmer, N. McCabe, C.J. Lord, A.N. Tutt, D.A. Johnson, and T.B. Richardson et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy Nature 434 2005 917 921
10. J.F. Haince, M. Rouleau, M.J. Hendzel, J.Y. Masson, and G.G. Poirier Targeting poly(ADP-ribosyl)ation: a promising approach in cancer therapy Trends Mol Med 11 10 2005 456 463
11. A. Chen PARP inhibitors: its role in treatment of cancer Chin J Cancer 30 2011 463 471
12. N. Saleh-Gohari, H.E. Bryant, N. Schultz, K.M. Parker, T.N. Cassel, and T. Helleday Spontaneous homologous recombination is induced by collapsed replication forks that are caused by endogenous DNA single-strand breaks Mol Cell Biol 25 2005 7158 7169
13. C. Arnaudeau, C. Lundin, and T. Helleday DNA double-strand breaks associated with replication forks are predominantly repaired by homologous recombination involving an exchange mechanism in mammalian cells J Mol Biol 307 2001 1235 1245
14. J.P. Banath, D. Klokov, S.H. MacPhail, C.A. Banuelos, and P.L. Olive Residual gammaH2AX foci as an indication of lethal DNA lesions BMC Cancer 10 2010 4
15. S.B. Kaye, J. Lubinski, U. Matulonis, J.E. Ang, C. Gourley, and B.Y. Karlan et al. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer J Clin Oncol 30 2011 372 379
16. A.J. Wilson, A.S. Lalani, E. Wass, J. Saskowski, and D. Khabele Romidepsin (FK228) combined with cisplatin stimulates DNA damage-induced cell death in ovarian cancer Gynecol Oncol 127 2012 579 586
17. I.V. Gregoretti, Y.M. Lee, and H.V. Goodson Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis J Mol Biol 338 2004 17 31
18. M. Koprinarova, P. Botev, and G. Russev Histone deacetylase inhibitor sodium butyrate enhances cellular radiosensitivity by inhibiting both DNA nonhomologous end joining and homologous recombination DNA Repair (Amst) 10 2011 970 977
19. S. Adimoolam, M. Sirisawad, J. Chen, P. Thiemann, J.M. Ford, and J.J. Buggy HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination Proc Natl Acad Sci U S A 104 2007 19482 19487
20. B. Ladd, J.J. Ackroyd, J.K. Hicks, C.E. Canman, S.A. Flanagan, and D.S. Shewach Inhibition of homologous recombination with vorinostat synergistically enhances ganciclovir cytotoxicity DNA Repair (Amst) 12 2013 1114 1121
21. B.S. Mann, J.R. Johnson, M.H. Cohen, R. Justice, and R. Pazdur FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma Oncologist 12 2007 1247 1252
22. B.S. Mann, J.R. Johnson, K. He, R. Sridhara, S. Abraham, and B.P. Booth et al. Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma Clin Cancer Res 13 2007 2318 2322
23. D. Khabele, D.S. Son, A.K. Parl, G.L. Goldberg, L.H. Augenlicht, and J.M. Mariadason et al. Drug-induced inactivation or gene silencing of class I histone deacetylases suppresses ovarian cancer cell growth: implications for therapy Cancer Biol Ther 6 2007 795 801
24. A.J. Wilson, E. Holson, F. Wagner, Y.L. Zhang, D.M. Fass, and S.J. Haggarty et al. The DNA damage mark pH2AX differentiates the cytotoxic effects of small molecule HDAC inhibitors in ovarian cancer cells Cancer Biol Ther 12 2011 484 493
25. P.L. Lorenzi, W.C. Reinhold, S. Varma, A.A. Hutchinson, Y. Pommier, and S.J. Chanock et al. DNA fingerprinting of the NCI-60 cell line panel Mol Cancer Ther 8 2009 713 724
26. D.A. Scudiero, A. Monks, and E.A. Sausville Cell line designation change: multidrug-resistant cell line in the NCI anticancer screen J Natl Cancer Inst 90 1998 862
27. C. DelloRusso, P.L. Welcsh, W. Wang, R.L. Garcia, M.C. King, and E.M. Swisher Functional characterization of a novel BRCA1-null ovarian cancer cell line in response to ionizing radiation Mol Cancer Res 5 2007 35 45
28. B. Effron, and R. Tibshirani On testing the significance of sets of genes Ann Appl Stat 1 2007 107 129
29. T.C. Chou, and P. Talalay Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors Adv Enzyme Regul 22 1984 27 55
30. A.J. Wilson, D. Arango, J.M. Mariadason, B.G. Heerdt, and L.H. Augenlicht TR3/Nur77 in colon cancer cell apoptosis Cancer Res 63 2003 5401 5407
31. A.J. Wilson, D.S. Byun, S. Nasser, L.B. Murray, K. Ayyanar, and D. Arango et al. HDAC4 promotes growth of colon cancer cells via repression of p21 Mol Biol Cell 19 2008 4062 4075
32. C. Rauh-Adelmann, K.M. Lau, N. Sabeti, J.P. Long, S.C. Mok, and S.M. Ho Altered expression of BRCA1, BRCA2, and a newly identified BRCA2 exon 12 deletion variant in malignant human ovarian, prostate, and breast cancer cell lines Mol Carcinog 28 2000 236 246
33. C. Zhou, P. Huang, and J. Liu The carboxyl-terminal of BRCA1 is required for subnuclear assembly of RAD51 after treatment with cisplatin but not ionizing radiation in human breast and ovarian cancer cells Biochem Biophys Res Commun 336 2005 952 960
34. X. Chen, P. Wong, E.H. Radany, J.M. Stark, C. Laulier, and J.Y. Wong Suberoylanilide hydroxamic acid as a radiosensitizer through modulation of RAD51 protein and inhibition of homology-directed repair in multiple myeloma Mol Cancer Res 10 2012 1052 1064
35. T. Suzuki, and N. Miyata Non-hydroxamate histone deacetylase inhibitors Curr Med Chem 12 2005 2867 2880
36. S.C. Modesitt, M. Sill, J.S. Hoffman, and D.P. Bender A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study Gynecol Oncol 109 2008 182 186
37. S. Bhaskara, B.J. Chyla, J.M. Amann, S.K. Knutson, D. Cortez, and Z.W. Sun et al. Deletion of histone deacetylase 3 reveals critical roles in S phase progression and DNA damage control Mol Cell 30 2008 61 72
38. S. Bhaskara, S.K. Knutson, G. Jiang, M.B. Chandrasekharan, A.J. Wilson, and S. Zheng et al. Hdac3 is essential for the maintenance of chromatin structure and genome stability Cancer Cell 18 2010 436 447
39. J.E. Bradner, N. West, M.L. Grachan, E.F. Greenberg, S.J. Haggarty, and T. Warnow et al. Chemical phylogenetics of histone deacetylases Nat Chem Biol 6 2010 238 243